@article{oai:repo.qst.go.jp:00049141,
 author = {大島, 康宏 and 須藤, 仁美 and 渡辺, 茂樹 and 永津, 弘太郎 and 辻, 厚至 and 坂下, 哲哉 and 伊藤, 陽一 and 吉永, 恵一郎 and 東, 達也 and 石岡, 典子 and 大島 康宏 and 須藤 仁美 and 渡辺 茂樹 and 永津 弘太郎 and 辻 厚至 and 坂下 哲哉 and 吉永 恵一郎 and 東 達也 and 石岡 典子},
 issue = {6},
 journal = {European Journal of Nuclear Medicine and Molecular Imaging},
 month = {Jan},
 note = {Purpose: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. β-emitting radiopharmaceutical meta-131I-iodo-benzylguanidine (131I-MIBG) has limited survival benefits and adverse effects. A new generation of radionuclide therapy using α-particles including meta-211At-astatobenzylguanidine (211At-MABG) is expected to have strong therapeutic effects with minimal side effects. However, this possibility has not been evaluated in a pheochromocytoma animal model. We aimed to evaluate the therapeutic effects of α-emitter 211At-MABG on a pheochromocytoma model. 
Methods: We evaluated tumor volume-reduction effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. PC12 tumor-bearing mice received 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; n = 5 each group) intravenously. The tumor volume was evaluated until 8 weeks after 211At-MABG administration. Control group (n = 10) received phosphate buffered saline (PBS).
Results: The single 211At-MABG therapy showed significantly lower relative tumor growth until 38 days compared to control [relative tumor volume, control: 509.2% ± 169.1% vs. 9.6% ± 5.5% (0.56 MBq) at day 21, p < 0.01]. In addition, the 211At-MABG treatment groups with 0.28, 0.56 and 1.11 MBq showed only temporary weight reduction, recovering weight loss at day 10.
Conclusion: 211At-MABG exhibited a strong tumor volume-reduction effect in a pheochromocytoma mouse model without weight reduction. Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma.},
 pages = {999--1010},
 title = {Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model},
 volume = {45},
 year = {2018}
}